Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Isn't this the strong base for Precision Medicine?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Steady_T Member Profile
Member Level 
Followed By 108
Posts 12,473
Boards Moderated 3
Alias Born 12/09/04
160x600 placeholder
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/16/2019 6:01:11 AM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 7/3/2019 4:33:43 PM
Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in P... GlobeNewswire Inc. - 6/25/2019 7:00:00 AM
Steady_T Member Level  Saturday, 09/21/19 05:18:10 PM
Re: nidan7500 post# 210921
Post # of 214456 
Quote:
Isn't this the strong base for Precision Medicine? The search for and application of those relevant facts/hard data that can be measured and correlated.



Sort of. As I understand it, precision medicine allows Drs to determine in advance if a drug or treatment will work for an individual patient. Implicit in that is that the drug or treatment doesn't work for everyone so the precision part allows the use of a test or biomarker to determine which patients will benefit. That saves time and money.

The other side of that is if the drug or treatment works for all patients then there is no need for the precision medicine.

For 2-73 and AD, the current information is that 2-73 will have a positive effect for all of the genotypes. It will have a stronger effect on those patients with the wild type genes. If that is the case 2-73 will be prescribed for all AD patients. Maybe those with the mutated gene form will get a stronger dose?

Right now the distinction is only being used to allow for statistical analysis of the two groups. If the response difference holds up to statistical analysis then the company will have to decide what to do with that information.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist